Evaluating the association between avascular necrosis of femoral head and oral corticosteroids use in Taiwan

Shih-Wei Lai, MD, a,b,∗ Cheng-Li Lin, MS, a,c Kuan-Fu Liao, MD, PHD, d,e,*

Abstract
The aim of this study was to assess a correlation between avascular necrosis of femoral head and oral corticosteroids use in the general population in Taiwan. A population-based case-control study was performed to analyze the database of Taiwan National Health Insurance Program. The study consisted of 3002 subjects aged 20 to 84 with newly diagnosed avascular necrosis of femoral head between 2000 and 2013 as the cases and 11279 sex-matched and age-matched subjects without avascular necrosis of femoral head as the matched controls. Use of oral corticosteroids was defined as subjects who had at least a prescription for oral corticosteroids before the index date. No use of oral corticosteroids was defined as subjects who did not have a prescription for oral corticosteroids before the index date. The logistic regression model revealed that subjects with avascular necrosis of femoral head were 1.65 times more likely to be exposed to oral corticosteroids than those subjects without avascular necrosis of femoral head (OR 1.65, 95% CI = 1.51–1.80). A sub-analysis revealed that there was a significant association between avascular necrosis of femoral head and increasing cumulative duration of oral corticosteroids for each additional month of use (OR 1.03, 95% CI = 1.02–1.03). A significant association is detected between avascular necrosis of femoral head and oral corticosteroids use in the general population in Taiwan. There is a duration-dependent effect of oral corticosteroids use on the risk of avascular necrosis of femoral head. Clinicians should be aware of the risk of avascular necrosis of femoral head when oral corticosteroids are prescribed for a long time.

Abbreviation: ICD-9 code = International Classification of Diseases, 9th Revision, Clinical Modification.

Keywords: avascular necrosis, case-control study, femoral head, oral corticosteroids, Taiwan National Health Insurance Program

1. Introduction
Avascular necrosis of femoral head is defined as a reduction of blood supply to femoral head resulting in cellular death, head collapse, and finally secondary osteoarthritis of hip joint.[1,2] Avascular necrosis of femoral head is a progressive debilitating disease with irreversible destruction of hip joint and eventually needing total hip arthroplasty.[3,4] From a view of preventive medicine, primary prevention, and early detection are important because the stage and location of avascular necrosis of femoral head will affect the prognosis.[4,5] To date, wide range of risk factors has been described, including trauma, alcohol consumption, and corticosteroids use.[6–8]

Some epidemiological studies have shown the correlation between avascular necrosis of femoral head and other comorbidities.[9–11] An observational study in Taiwan showed that corticosteroids use accounted for 21.7% of the etiologies for avascular necrosis of femoral head,[12] but this study only used
one hospital record and it could not be extrapolated to the general population in Taiwan. An observational study in Taiwan showed that avascular necrosis of femoral head was the leading cause of total hip replacement (accounting for 46.9% of cases with total hip replacement). An observational study reported that at least 76% of the general population in Taiwan has ever used corticosteroids. Based on the above review, we made a plausible hypothesis that there could be a link between avascular necrosis of femoral head and corticosteroid use in the general population in Taiwan. Given avascular necrosis of femoral head causing a serious outcome, if a link between avascular necrosis of femoral head and corticosteroids use really exists in the general population, active surveillance for femoral head and harm reduction program should be suggested among corticosteroid users. Therefore, a population-based study was performed to address the following objectives:

1. Whether there is a possible correlation between avascular necrosis of femoral head and oral corticosteroids use in the general population in Taiwan?
2. Whether there is a duration-dependent effect of oral corticosteroids use on the risk of avascular necrosis of femoral head?

2. Methods

2.1. Study design and data source

A population-based case-control study was conducted to analyze the database of the Taiwan National Health Insurance Program. The program was launched in March 1995 and has covered 99.7% of 23 million residents living in Taiwan. The details of the program can be found in previous studies.

2.2. Study subjects

Subjects aged 20 to 84 years with newly diagnosed avascular necrosis of femoral head during the period between 2000 and 2013 were selected as the cases (based on International Classification of Disease, 9th Revision of Clinical Modification [ICD-9] code 733.42). The diagnosis date of avascular necrosis of femoral head was defined as the index date. In addition, for every case with avascular necrosis of femoral head, approximately 4 subjects aged 20 to 84 years without a diagnosis of avascular necrosis of femoral head were selected from the same database as the controls. The cases and the controls were matched for sex, age (every 5-year span), comorbidities, and the year of the index date.

2.3. Definition of oral corticosteroids use

Oral corticosteroids in Taiwan during 2000–2013 were included as follows: cortisone, dexamethasone, fluocortisone, methylprednisolone, prednisolone, and triamcinolone. The definition of oral corticosteroids use was adapted from previous studies. Use of oral corticosteroids was defined as subjects who had at least a prescription for oral corticosteroids before the index date. No use of oral corticosteroids was defined as subjects who did not have a prescription for oral corticosteroids before the index date.

2.4. Comorbidities studied

Comorbidities before the index date were selected as follows: alcohol-related disease, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, hyperlipidemia, and hypertension, as well as cardiovascular disease including coronary artery disease, heart failure, cerebrovascular disease, and peripheral atherosclerosis. All comorbidities were diagnosed based on ICD-9 codes, which have been well assessed in previous studies.

To increase the analysis validity, subjects having at least 2 episodes of the same diagnosis for avascular necrosis of femoral head and comorbidities during the ambulatory care and/or having at least one episode of hospitalization diagnosis could be included in the study. Principal diagnosis and secondary diagnosis were equally applied. Such stringent criteria were adapted from previous studies.

2.5. Statistical analysis

The differences of the demographic status, oral corticosteroids use, and comorbidities between the cases and the matched controls were assessed by using the Chi-square test for categorized variables and the t test for continuous variables. All variables were tested by the logistic regression model. The odds ratio and the 95% confidence interval were used to assess the correlation between avascular necrosis of femoral head and oral corticosteroids use. A further analysis was conducted to assess the correlation between avascular necrosis of femoral head and cumulative duration of oral corticosteroids use. Analyses were performed by using the SAS 9.2 version (SAS Institute Inc., Carey, North Carolina), with P < .05 as statistically significant.

3. Results

3.1. Basic information of the study population

Table 1 revealed the distributions of sex, age, oral corticosteroids use, and comorbidities between the cases and the matched controls. The study included 3002 cases with avascular necrosis of femoral head and 11279 matched controls, with similar distributions of sex and age. The mean ages (standard deviation) of the study subjects were 52.9 (14.6) in the cases and 52.7 (14.8) in the controls. The study included 3002 cases with avascular necrosis of femoral head and cumulative duration of oral corticosteroids use. The differences of the demographic status, oral corticosteroids use, and comorbidities between the cases and the matched controls were assessed by using the Chi-square test for categorized variables and the t test for continuous variables. All variables were tested by the logistic regression model. The odds ratio and the 95% confidence interval were used to assess the correlation between avascular necrosis of femoral head and oral corticosteroids use. A further analysis was conducted to assess the correlation between avascular necrosis of femoral head and cumulative duration of oral corticosteroids use. Analyses were performed by using the SAS 9.2 version (SAS Institute Inc., Carey, North Carolina), with P < .05 as statistically significant.

3.2. Association between avascular necrosis of femoral head and oral corticosteroids use

Table 2 revealed the association between avascular necrosis of femoral head and oral corticosteroids use. Because other variables studied were not significantly associated with avascular necrosis of femoral head in a univariable logistic regression model, the multivariable logistic regression model was not performed. The univariable logistic regression model revealed that there was a significant association between avascular necrosis of femoral head and oral corticosteroids use (OR 1.65, 95% CI: 1.51–1.80). A sub-analysis in Table 3 revealed that there was a significant association between avascular necrosis of femoral head and increasing cumulative duration of oral corticosteroids for each additional month of use (OR 1.03, 95% CI: 1.02–1.03).
4. Discussion

In this present study, subjects with avascular necrosis of femoral head were 1.65 times more likely to be exposed to oral corticosteroids than those subjects without avascular necrosis of femoral head, which was compatible with previous studies. In a further analysis, subjects with avascular necrosis of femoral head were 1.55 times more likely to be exposed to oral corticosteroids <12 months than those without avascular necrosis of femoral head, which was partially compatible with a previous study revealing that patients would develop avascular necrosis of femoral head within 12 months of initiating corticosteroids use. In addition, subjects with avascular necrosis of femoral head were 4.7 times more likely to be exposed to oral corticosteroids ≥12 months than those without avascular necrosis of femoral head. These findings indicate that there appears to a duration-dependent effect of oral corticosteroids use on the risk of avascular necrosis of femoral head. That is, the longer the duration of oral corticosteroids use, the greater the risk of avascular necrosis of femoral head.

The current literature on the mechanisms underlying the association between avascular necrosis of femoral head and oral corticosteroids use was summarized as follows. The animal models revealed that hyperlipidemia and increased free fatty acids were detected in rabbits with corticosteroid-induced avascular necrosis of femoral head. These circulating lipids are likely to develop systemic fat emboli, which slow blood flow and compromise blood supply to the affected femoral head, and eventually cause death of affected bone cells. These}

| Variable | OR (95% CI) |
|----------|-------------|
| Sex (male vs female) | 0.98 (0.90, 1.07) |
| Age (every 1 yr) | 1.00 (0.99, 1.00) |
| Use of oral corticosteroids (no use as a reference) | 1.65 (1.51, 1.80) |
| Comorbidity before index date (yes vs no) | |
| Alcohol-related disease | 1.08 (0.97, 1.21) |
| Cardiovascular disease | 1.02 (0.93, 1.11) |
| Chronic kidney disease | 1.06 (0.91, 1.22) |
| Chronic obstructive pulmonary disease | 1.02 (0.92, 1.12) |
| Diabetes mellitus | 1.03 (0.89, 1.20) |
| Hypertension | 1.01 (0.92, 1.11) |
| Hypertension | 1.01 (0.93, 1.10) |

Because other variables studied were not significantly associated with avascular necrosis of femoral head in a univariable model, the multivariable model was not performed.

CI = confidence interval, OR = Odds ratio.

Table 3

| Variable | Case number /control number | OR (95% CI) |
|----------|-----------------------------|-------------|
| No use of oral corticosteroids as a reference | 864/4511 | 1.00 (reference) |
| Cumulative duration of oral corticosteroids use (increase in duration for every one month) | 2138/6768 | 1.03 (1.02, 1.03) |
| Cumulative duration of oral corticosteroids use <12 mo | 1947/6556 | 1.55 (1.42, 1.69) |
| Cumulative duration of oral corticosteroids use ≥12 mo | 191/212 | 4.70 (3.82, 5.80) |

Because other variables studied were not significantly associated with avascular necrosis of femoral head in a univariable model, the multivariable model was not performed.

CI = confidence interval, OR = Odds ratio.
mechanisms represent a potential pathway of corticosteroid-associated avascular necrosis of femoral head. It can be partially supported by the evidence that statins are lipid-lowering agents, which can be associated with reduced risk of corticosteroid-related avascular necrosis of femoral head in animal and human studies.\(^{[17-40]}\)

5. Limitation

Some limitations should be discussed. First, due to inborn limitation of the database, socioeconomic factors and traditional medicines use were not recorded in the database. It was unable to quantify the use of traditional medicines, which might contain undeclared corticosteroids. In addition, alcohol-related disease was used instead of alcohol consumption. This point has been mentioned in previous studies.\(^{[41,42]}\) Second, due to the same limitation, the etiologic factor of avascular necrosis of femoral head was not recorded in the database. The traumatic or non-traumatic cause could not be differentiated. Third, due to a case-control design, whether the timing of corticosteroids use was before or after the onset of avascular necrosis of femoral head could not be differentiated. However, cases in this present study were those subjects with newly diagnosed avascular necrosis of femoral head, so corticosteroids really were used before the diagnosis of avascular necrosis of femoral head.

6. Conclusion

A significant association is detected between avascular necrosis of femoral head and oral corticosteroids use in the general population in Taiwan. There is a duration-dependent effect of oral corticosteroids use on the risk of avascular necrosis of femoral head. Clinicians should be aware of the risk of avascular necrosis of femoral head when oral corticosteroids are prescribed for a long time.

Author contributions

Conceptualization: Shih-Wei Lai.

Formal analysis: Cheng-Li Lin, Kuan-Fu Liao.

Investigation: Shih-Wei Lai.

Supervision: Shih-Wei Lai.

Writing – original draft: Shih-Wei Lai.

Writing – review and editing: Shih-Wei Lai.

References

[1] Moya-Angeler J, Gianakos AL, Villa JC, et al. Current concepts on osteonecrosis of the femoral head. World J Orthop 2015;6:590–601.
[2] Guerado E, Caso E. The physiopathology of avascular necrosis of the femoral head: an update. Injury 2016;47:S16–26.
[3] Mont MA, Jones LC, Einhorn TA, et al. Osteonecrosis of the femoral head. Potential treatment with growth and differentiation factors. Clin Orthop Relat Res 1998;353:S14–35.
[4] Zalavras CG, Lieberman JR. Osteonecrosis of the femoral head: evaluation and treatment. J Am Acad Orthop Surg 2014;22:455–64.
[5] Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 2002;32:94–124.
[6] Jacobs B. Epidemiology of traumatic and nontraumatic osteonecrosis. Clin Orthop Relat Res 1978;130:51–67.
[7] Bradford JK, Morrey BF. The natural history of the silent hip in bilateral atraumatic osteonecrosis. J Arthroplasty 1993;8:383–7.
[8] Ikuchi K, Hasegawa Y, Seki T, et al. Epidemiology of nontraumatic osteonecrosis of the femoral head in Japan. Mod Rheumatol 2015;25:278–81.
[9] Hung TH, Hsieh YH, Tsai CC, et al. Is liver cirrhosis a risk factor for osteonecrosis of the femoral head in adults? A population-based 3-year follow-up study. Intern Med 2011;50:563–8.
[10] Sung IH, Yang YH, Chiang HJ, et al. Cardiovascular and cerebrovascular events are associated with nontraumatic osteonecrosis of the femoral head. Clin Orthop Relat Res 2018;476:665–74.
[11] Lai SW, Lin CL, Liao KF. Real-world database examining the association between avascular necrosis of the femoral head and diabetes in Taiwan. Diabetes Care 2019;42:39–43.
[12] Tsai SW, Wu PK, Chen CF, et al. Etiologies and outcome of osteonecrosis of the femoral head: etiology and outcome study in a Taiwan population. J Clin Med Assoc 2016;79:39–45.
[13] Lai YS, Wei HW, Cheng CK. Incidence of hip replacement among national health insurance enrollees in Taiwan. J Orthop Surg Res 2008;33:3–42.
[14] Lai SW, Lin CL, Liao KF. Nation-based case-control study investigating the relationship between oral corticosteroids use and pulmonary tuberculosis. Eur J Intern Med 2017;43:53–7.
[15] Ministry of Health and Welfare Taiwan. 2018 Taiwan Health and Welfare Report. http://www.mohw.gov.tw [cited on November 1, 2019, English version].
[16] Lai SW, Lin CL, Liao KF. Weight loss might be an early clinical manifestation of undiagnosed cancer: a nation-based cohort study. Biomedicine 2018;8:23–7.
[17] Liao KF, Lin CL, Lai SW. Association between colorectal cancer and thiazolidinediones administration in a case-control study. Biomedicine 2019;9:31–6.
[18] Lai SW, Liao KF, Liao CC, et al. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine 2010;89:295–9.
[19] Wang IK, Lai SW, Lai HC, et al. Risk of and fatality from acute pancreatitis in long-term hemodialysis and peritoneal dialysis patients. Perit Dial Int 2018;38:30–6.
[20] Liao KF, Lin CL, Lai SW. Association between allopurinol use and hepatocellular carcinoma in a case-control study in Taiwan. Eur J Hosp Pharm 2019;26:258–61.
[21] Lin HF, Liao KF, Chang CM, et al. Association of use of selective serotonin reuptake inhibitors with risk of acute pancreatitis: a case-control study in Taiwan. Eun J Clin Pharmacol 2017;73:1615–21.
[22] Cheng KC, Liao KF, Lin CL, et al. Correlation of proton pump inhibitors with pulmonary tuberculosis: a case-control study in Taiwan. Front Pharmacol 2017;8:481.
[23] Lin HF, Liao KF, Chang CM, et al. Correlation of the tamoxifen use with the increased risk of deep vein thrombosis and pulmonary embolism in elderly women with breast cancer: a case-control study. Medicine 2018;97:e12842.
[24] Liao KF, Cheng KC, Lin CL, et al. Etdolac and the risk of acute pancreatitis. Biomedicine 2017;7:25–9.
[25] Hung SC, Lin CH, Hung HC, et al. Use of selective serotonin reuptake inhibitors and risk of hip fracture in the elderly: a case-control study in Taiwan. J Am Med Dir Assoc 2017;18:350–4.
[26] Lin HF, Liao KF, Chang CM, et al. Tamoxifen usage correlates with increased risk of Parkinson’s disease in older women with breast cancer: a case-control study in Taiwan. Eur J Clin Pharmacol 2018;74:99–107.
[27] Lin HF, Liao KF, Chang CM, et al. Use of thiazolidinediones and risk of hip fracture in old people in a case-control study in Taiwan. Medicine 2017;96:e7712.
[28] Hung SC, Liao KF, Hung HC, et al. Tamoxifen use correlates with increased risk of hip fractures in older women with breast cancer: a case-control study in Taiwan. Geriatr Gerontol Int 2019;19:56–60.
[29] Lai SW, Lin CL, Liao KF. Use of oral corticosteroids and risk of hip fracture in the elderly in a case-control study. Front Pharmacol 2017;8:625.
[30] Sagakuichi M, Tanaka T, Fukushima W, et al. Impact of oral corticosteroid use for idiopathic osteonecrosis of the femoral head: a nationwide multicenter case-control study in Japan. J Orthop Sci 2010;15:185–91.
[31] Koo KH, Kim R, Kim YS, et al. Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment. Clin Rheumatol 2002;21:299–303.
[32] Jaffe WL, Epstein M, Heyman N, et al. The effect of cortisone on femoral and humeral heads in rabbits. An experimental study. Clin Orthop Relat Res 1972;82:221–8.

[33] Kabata T, Kubo T, Matsumoto T, et al. Onset of steroid-induced osteonecrosis in rabbits and its relationship to hyperlipaemia and increased free fatty acids. Rheumatology 2005;44:1233–7.

[34] Motomura G, Yamamoto T, Miyanishi K, et al. Risk factors for developing osteonecrosis after prophylaxis in steroid-treated rabbits. J Rheumatol 2008;35:2391–4.

[35] Weldon D. The effects of corticosteroids on bone: osteonecrosis (avascular necrosis of the bone). Ann Allergy Asthma Immunol 2009;103:91–7.

[36] Fisher DE. The role of fat embolism in the etiology of corticosteroid-induced avascular necrosis: clinical and experimental results. Clin Orthop Relat Res 1978;130:68–80.

[37] Iwakiri K, Oda Y, Kaneshiro Y, et al. Effect of simvastatin on steroid-induced osteonecrosis evidenced by the serum lipid level and hepatic cytochrome P4503A in a rabbit model. J Orthop Sci 2008;13:463–8.

[38] Nozaki Y, Kusagai K, Miyata N, et al. Pravastatin reduces steroid-induced osteonecrosis of the femoral head in SHRSP rats. Acta Orthop 2012;83:87–92.

[39] Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res 2001;386:173–8.

[40] Ajmal M, Matas AJ, Kuskowski M, et al. Does statin usage reduce the risk of corticosteroid-related osteonecrosis in renal transplant population? Orthop Clin North Am 2009;40:235–9.

[41] Lai SW, Lin CL, Liao KF. Atrial fibrillation associated with acute pancreatitis: a retrospective cohort study in Taiwan. J Hepatobiliary Pancreat Sci 2016;23:242–7.

[42] Lin HF, Liao KF, Chang CM, et al. Population-based cohort study examining the association between splenectomy and empyema in adults in Taiwan. BMJ Open 2017;7:e015101.